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BIP = BRCA1- and BRCA1-interacting protein; DSB = double-stranded break; NHEJ = nonhomologous end-joining protein; TCR = T-cell receptor.
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Mutation in the human BRCA1 gene is thought to account
for 45% of familial cancers and for more than 80% of
inherited ovarian cancers. Its identification and mapping to
chromosome arm 17q, in 1990, was followed by intense
efforts to isolate the gene. It therefore came as something
of a surprise in 1994 when the gene was isolated and
found to encode a 1863-amino-acid protein that was
expressed in a wide variety of tissues, with highest expres-
sion in the thymus and testes. The flurry of publications
that followed the isolation of the BRCA1 gene has slowly
begun to put these initial findings into perspective. One of
the most important of these has been the observation that
BRCA1 plays a major role in DNA damage repair.
DNA repair proteins play a central role in T-cell lineage
development because they act to ligate or repair DNA
double-stranded breaks (DSBs) that occur during the initi-
ation of V(D)J recombination of the T-cell receptor (TCR).
For this reason, Mak et al [1] sought to determine the role
of BRCA1 in T-cell maturation and function. By using the
Cre/lox/P system to generate mice with a homozygous
deletion of brca1 exons 5 and 6 restricted to the T-cell
compartment (mice homozygous for the ‘floxed’ brca1
exons were crossed with transgenic mice expressing the
Cre recombinase under the control of the T-cell specific
lck promoter), those investigators were able to study T-cell
brca1 function while also circumventing the early embry-
onic lethality associated with the brca1 mutation.
To their surprise, Mak et al found that T cells from mice
that lacked brca1 showed no abnormality in rearrange-
ment of the TCR loci. What they observed instead was a
significant (90%) depletion of the thymocytes, with a
developmental defect occurring at some point after the
very ‘immature’ double-negative stage of T-lymphocyte
maturation. The most interesting part of this work is what
they found on application of the brca1 mutant to different
genetic backgrounds.
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Abstract
Recent work by Mak et al demonstrates that mice carrying a T-cell-specific disruption of the brca1
gene display markedly impaired T-lymphocyte development and proliferation in the absence of any
increased tendency for the formation of tumors. Interestingly, the extent of these defects was found to
be highly dependent on cellular context. Contrasting the rather broad tissue expression pattern of
brca1 against its exquisitely selective etiologic role in cancers of the breast and ovary, many of us are
left to ponder – where is the specificity?
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Prior transgenic studies with the brca1 gene [2,3]
revealed that loss of brca1 function is associated with an
increase in the expression and activity of the p53 tumor
suppressor gene. The increased levels of p53 is thought
to occur in response to the marked accumulation of chro-
mosomal abnormalities in cells that carry the brca1 muta-
tion, an observation that is consistent with a role for brca1
in DNA repair. The high levels of p53 increase the tran-
scription of genes that are involved in growth inhibition
and apoptosis – including p21 and Bax – and is a major
contributor to the early embryonic lethality associated with
the brca1 mutation. Increases in p53, p21 and Bax, as
well as increased apoptosis and sensitivity to ionizing radi-
ation, were demonstrated in the thymocytes carrying the
targeted brca1 mutation.
Moreover, application of the brca1 mutation in a p53-null
genetic background led to significant thymocyte rescue
with full recovery of cells in the thymus and 70% recovery
of cells in the lymph node. Not surprisingly, these
‘rescued’ double-mutant cells showed multiple cytoge-
netic changes, an observation that affirms the ‘caretaker’
role of brca1 as a guardian of the genome. Notably, the
effects of genetic background were dependent on the T-
cell context. Expression of the brca1 mutant in a p21-null
background caused little rescue of the cells in the thymus,
but provided a recovery in the lymph nodes that was
equivalent to that produced in the p53-null background.
Introduction of the brca1 gene in cells carrying an anti-
apoptotic Bcl2 transgene induced significant rescue of
cells in the thymus, but produced little recovery of cells in
peripheral (lymph node) compartments. A possible expla-
nation for this observation is that cells of the thymus (a
mainly nonprofilerating compartment) are much more sen-
sitive to apoptosis, whereas those in the peripheral lymph
nodes (a rapidly proliferating compartment) are much
more influenced by components that induce cell cycle
arrest. Indeed, the relative sensitivity to apoptosis versus
cell cycle arrest varies between cellular compartments
and/or cell types. Such differences probably occur
through a hierarchy of cell-specific and pathway-specific
programs of cellular behavior.
So how might the lack of a single gene effect cells of dif-
ferent origins so divergently? The answer may lie in two
biochemically distinct consequences of the loss of brca1
function.
The first is the resultant increase in chromosome abnor-
malities, namely DNA DSBs, which are observed in the
brca1 mutants. A key feature that may differentiate a cell’s
response to brca1 deficiency is how robustly it may react
to increased DSB levels. Tissue types that are actively
engaged in DNA repair/recombination activities (such as
thymus, spleen, and testes) may have a greater surveil-
lance for loss of integrity of the genome that results from
brca1 deficiency. Affected cells would be more rapidly
removed from the population through the action of ‘gate-
keeper’ genes such as p53. Support for this notion comes
from what we have learned from model systems in which
other DNA repair genes have been deleted. This includes
the class of nonhomologous end-joining proteins (NHEJs),
which are important components of DNA repair [4]. These
proteins include XRCC4, DNA-PK, the Ku 80/86 proteins
and DNA ligase IV, and they function to repair random
DNA breaks that are produced by genotoxic agents (eg
ionizing radiation) and specific breaks that occur during
programmed gene rearrangement (eg V[D]J joining of the
TCR). Loss of function of these genes leads to decreased
and/or error-prone DSB repair. In many cases the NHEJ
deficiency led to increased apoptosis in the selected
tissues, and in several the application of the deficiency to
a p53-null background increased survival and the inci-
dence of lymphoid tumors [5,6].
Using a similar approach, a conditional mutation of brca1
in mammary epithelia was found to lead to rapid tumor for-
mation when introduced into a p53-null background [7].
Interestingly, mammary tumor formation in the presence of
p53 occurred after a long latency, and many of the tumors
were associated with genetic instability and alteration of
p53 transcription. In this example, the loss of p53 function
may have been a direct consequence of genetic instability.
In this regard, it would be interesting to determine whether
NHEJ-deficient mice that survive their lymphoid tumors go
on to develop tumors of any other organ.
So is it just that simple? Could the tissue specificity of
BRCA1-linked tumors reflect a careful balance between
the ‘caretakers’ and ‘gatekeepers’ of the cell and the pro-
grammed requirements of the cell for DNA damage sur-
veillance? Could the organ susceptibility of the BRCA1
mutation simply reflect the fact that the mammary gland
gatekeepers have a greater tendency to ‘be asleep at the
wheel’ in the face of BRCA1 deficiency? Indeed, aspects
of these concepts are important in T-cell development
because immature T-cells are much more resistant to
p53-independent cell death pathways that are induced by
the presence of DSBs [8]. Thus, surveillance of gate-
keeper pathways can be influenced by both tissue type
and ontogeny.
The key to this solution will ultimately come from develop-
ing a better understanding of the second major biochemi-
cal consequence of BRCA1 deficiency: the loss of
functional complexes between BRCA1- and BRCA1-inter-
acting proteins (BIPs). BRCA1 contains several functional
domains that interact with a cavalcade of proteins, includ-
ing ATM, p53, RB, c-Myc, BRCA2, DNA repair factors,
E2F, and others. Many of the BIPs are proto-oncogenes or
tumor suppressors that can regulate transcription through
both direct and indirect mechanisms. What has becomec
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clear from the growing list of BIPs is that BRCA1 is proba-
bly involved in multiple biologic programs of cellular
behavior, including transcription, cell-cycle regulation,
DNA damage repair, centrosome duplication, and cell
growth and apoptosis. However, none of the BIPs identi-
fied thus far show a tissue restricted pattern of expression
that could explain the tissue tropism of brca1-related
cancers. Still the concept that the cellular outcome of
BRCA1 expression can be dictated by specific BIP
expression has been verified by the finding that a cell’s
susceptibility to brca1-induced cell cycle arrest is depen-
dent on the presence of RB [9].
Future emphasis will have to be placed on identifying those
cellular genes and gene products that become altered –
via transcriptional, post-transcriptional or post-translational
mechanisms – when there is a disruption in brca1 expres-
sion. Combined genomic and proteomic approaches will
be needed to unravel the mysteries of BRCA1 as both a
caretaker of the genome and as an essential component of
cellular homeostasis and development.
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